Similar Items: Corrigendum to “Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials”
- Optimizing Abrocitinib Use for Atopic Dermatitis in India: Expert Recommendations for Patient Selection, Dosing, and Long‑Term Remission
- Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)
- Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis
- Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)
- Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis
- Mental Health Among Caregivers of Children With Atopic Dermatitis: A Systematic Review With Meta‐Analysis